373 related articles for article (PubMed ID: 34479924)
21. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
22. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
24. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
25. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
26. Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Baetz T
J Immunother; 2021 Jan; 44(1):41-48. PubMed ID: 32815895
[TBL] [Abstract][Full Text] [Related]
27. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
28. Report on the 2018 Cancer, Autoimmunity, and Immunology Conference.
Curran CS; Sommers CL; Young HA; Bourcier K; Mancini M; Sharon E
J Immunol; 2019 May; 202(10):2823-2828. PubMed ID: 30988117
[TBL] [Abstract][Full Text] [Related]
29. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
30. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
31. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
32. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
33. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
34. B cells as biomarkers: predicting immune checkpoint therapy adverse events.
Liudahl SM; Coussens LM
J Clin Invest; 2018 Feb; 128(2):577-579. PubMed ID: 29309049
[TBL] [Abstract][Full Text] [Related]
35. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
[TBL] [Abstract][Full Text] [Related]
36. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
Cathcart-Rake EJ; Sangaralingham LR; Henk HJ; Shah ND; Riaz IB; Mansfield AS
Clin Lung Cancer; 2020 Sep; 21(5):421-427.e2. PubMed ID: 32446852
[TBL] [Abstract][Full Text] [Related]
37. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
38. Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events.
Cina ML; Venegas J; Young A
Immunol Rev; 2023 Sep; 318(1):110-137. PubMed ID: 37565407
[TBL] [Abstract][Full Text] [Related]
39. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
40. Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
Olsen TA; Zhuang TZ; Caulfield S; Martini DJ; Brown JT; Carthon BC; Kucuk O; Harris W; Bilen MA; Nazha B
Front Endocrinol (Lausanne); 2022; 13():779915. PubMed ID: 35392134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]